公开(公告)号：US20200323819A1

公开(公告)日：2020-10-15

申请号：US16791118

申请日：2020-02-14

Applicant: Sunovion Pharmaceuticals Inc. ,  PGI Drug Discovery LLC

Inventor： Liming SHAO ,  John Emmerson CAMPBELL ,  Michael Charles HEWITT ,  Una CAMPBELL ,  Taleen G. HANANIA

IPC: A61K31/381 ,  C07D277/60 ,  C07D333/54 ,  C07D333/76 ,  C07D333/78 ,  C07D495/04 ,  C07D495/20 ,  A61K31/435 ,  A61K31/55 ,  A61K45/06

Abstract: Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

公开(公告)号：US20200290987A1

公开(公告)日：2020-09-17

申请号：US16817749

申请日：2020-03-13

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Nandkumar Nivritti BHOGLE ,  Takahiko HASHIZUKA ,  Robert Joseph PRYTKO ,  John R. SNOONIAN ,  Harold Scott WILKINSON ,  Haitao ZHANG

IPC: C07D311/76

Abstract: The present disclosure relates to salts of (R)-1-(8-fluoroisochroman-1-yl)-N-methylmethanamine, crystalline forms thereof, and methods of preparation thereof, which are useful in the treatment of CNS disorders.

公开(公告)号：US20200237719A1

公开(公告)日：2020-07-30

申请号：US16846905

申请日：2020-04-13

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Seth Cabot Hopkins ,  Kenneth Stephen Koblan ,  John R. Snoonian ,  Harold Scott Wilkinson

IPC: A61K31/40 ,  A61P25/24

Abstract: Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are various formulations thereof, including, but not limited to, formulations employing polymorphs of enantiomeric amisulpride.

公开(公告)号：US20200179336A1

公开(公告)日：2020-06-11

申请号：US16704202

申请日：2019-12-05

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Seth Cabot HOPKINS

IPC: A61K31/381 ,  A61P25/18

Abstract: The present disclosure relates to methods of treating neurological or psychiatric diseases or disorders, such as schizophrenia. Compound 1, or a pharmaceutically acceptable salt thereof, is an antipsychotic agent with a non-D2 mechanism of action. Adverse events associated with antipsychotic agents that target the D2 dopamine receptor can be reduced by treating disorders with Compound 1, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20200147040A1

公开(公告)日：2020-05-14

申请号：US16738261

申请日：2020-01-09

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Seth Cabot Hopkins ,  Kenneth Stephen Koblan ,  John R. Snoonian ,  Harold Scott Wilkinson

IPC: A61K31/40 ,  A61P25/24

Abstract: Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are various formulations thereof, including, but not limited to, formulations employing polymorphs of enantiomeric amisulpride.

公开(公告)号：US10562916B2

公开(公告)日：2020-02-18

申请号：US15787880

申请日：2017-10-19

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： John Emmerson Campbell ,  Michael Charles Hewitt ,  Philip Xinhe Jones ,  Linghong Xie

IPC: A61K31/498 ,  C07D241/40 ,  C07D498/06 ,  C07D401/06 ,  C07D471/04 ,  C07D471/14 ,  C07D487/04 ,  C07D491/056 ,  C07D498/14 ,  C07D519/00 ,  C07D403/06 ,  C07D401/14 ,  C07D405/14 ,  C07D409/06 ,  C07D409/14 ,  C07D413/06 ,  C07D417/06 ,  C07D498/04 ,  A61K31/4164 ,  A61K31/4178 ,  A61K31/4709 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5383 ,  C07D233/58 ,  C07D471/06

Abstract: Provided herein are cyclic nucleotide phosphodiesterase inhibitors, and pharmaceutical compositions thereof, useful for the treatment of, for example, central nervous system and metabolic diseases and disorder.

公开(公告)号：US20200000746A1

公开(公告)日：2020-01-02

申请号：US16408701

申请日：2019-05-10

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： Thomas JERUSSI ,  Qun Kevin FANG ,  Mark G CURRIE

IPC: A61K31/135 ,  C07C211/42

Abstract: Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.

公开(公告)号：US10449146B2

公开(公告)日：2019-10-22

申请号：US15789528

申请日：2017-10-20

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Scott David Barnhart ,  Michael Clinton Koons ,  Madhu Sudan Hariharan ,  Jordan Dubow ,  Thierry Bilbault ,  Anthony John Giovinazzo

IPC: A61K9/00 ,  A61K47/02 ,  A61K31/473 ,  A61K45/06 ,  A61K47/14 ,  A61K47/26 ,  A61K47/36 ,  A61K9/70 ,  A61P25/16 ,  A61K47/10 ,  A61K47/18 ,  A61K47/38

Abstract: Methods and pharmaceutical unit dosage forms for treating Parkinson's disease in a subject (e.g., an “off” episode in a subject having Parkinson's disease) are described. The pharmaceutical unit dosage forms are films having a first portion including particles containing an acid addition salt of apomorphine and a second portion containing a pH neutralizing agent. The pharmaceutical unit dosage forms can be flexible and have toughness greater than 100 g×mm. The methods can involve administering to a subject having Parkinson's disease a therapeutic dose sufficient to produce an apomorphine plasma concentrate of at least 2.64 ng/mL within 45 minutes after the administration. The subject may be identified as having low uptake, medium uptake, or high uptake of apomorphine administered via oral mucosa.

公开(公告)号：US10435351B2

公开(公告)日：2019-10-08

申请号：US15882498

申请日：2018-01-29

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： Charles P. Vandenbossche ,  John R. Snoonian

IPC: C07C231/10 ,  C07C249/08 ,  C07C209/62 ,  C07C233/91 ,  C07C231/12 ,  C07C209/50

Abstract: A convenient method for converting oximes into enamides is disclosed. The process produces enamides without the concomitant production of a large volume of metallic waste. The enamides are useful precursors to amides and amines.

公开(公告)号：US10377708B2

公开(公告)日：2019-08-13

申请号：US16209263

申请日：2018-12-04

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： John R. Snoonian ,  Harold Scott Wilkinson

IPC: C07D207/09

Abstract: The various aspects present inventions provide various crystalline forms of (S)-(−)-amisulpride, (R)-(+)-amisulpride, and solvates thereof and methods of making same. In various aspects, the inventions also provide methods of resolving racemic amisulpride.